Baird raised the firm’s price target on Biogen (BIIB) to $300 from $294 and keeps an Outperform rating on the shares. The firm said Biogen partner Eisai’s request for the EMA’s CHMP to reexamine the ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

Reliance on a single customer for a huge chunk of revenue is weighing on this company, but that could turn into an advantage ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Future of Healthcategory Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest July 30, 2024 Businesscategory Shares of Japan's Eisai tumble after EU rejects ...

Economic stability impacts the accuracy of future stock price predictions; adjust accordingly. Key findings are powered by ChatGPT and based solely off the content from this article. Findings are ...

Eli Lilly stock has soared on a new growth wave driven ... I would argue that the market itself is still quite fragmented. For now, Biogen and Eisai are major players in the space thanks to ...

In comparison, stock market returns have been relatively muted, more so when the current round of correction is accounted for. Silver prices climbed about $10 an ounce since the beginning of the ...